If you have recently been diagnosed with COVID-19, you may be eligible for a research study.

Baylor University Medical Center, partnered with the Montreal Heart Institute, is investigating whether short-term treatment with a medicine called colchicine can prevent hospitalization, need for a ventilator, and death related to COVID-19.  The idea tested is to start colchicine early in the disease process, when you are feeling relatively ok, to prevent the development of severe symptoms.  

Colchicine is an anti-inflammatory drug that has been used for more than 2000 years to treat inflammatory conditions such as gout. We know that in COVID-19, people get severely ill partly due to the body’s overly robust immune response to the virus and colchicine dampens some parts of that type of immune response.

 You must meet the following criteria:
  • Diagnosed with definite or probable COVID-19 in the last 36 hrs
  • Not hospitalized
  • ≥ 40 years old
   If you participate, you will:
  • Take one pill twice a day for 3 days and then one pill daily for 27 days (even if you are feeling better)
  • Participate in 2 follow-up calls
  • May receive compensation up to $50

To participate, you do not need to leave the home. We will courier drug to your home (within 100 miles of Baylor University Medical Center).

If you meet the criteria listed above and would like to participate, contact us!

If you are a Baylor University Medical Center patient, contact us at (214)358-2300.
If you are not a Baylor University Medical Center patient or would like to call the study hotline directly, call 1-877-536-6837 (Montreal Heart Institute toll-free open 24/7)

Call as soon as possible, as the study is time sensitive.
You can also visit us at COLCORONA.NET for more information.

The Montreal Heart Institute Colcorona Study has received a grant from the COVID-19 Therapeutics Accelerator via the Bill & Melinda Gates Foundation.



View/Print PDF - English

View/Print PDF - Spanish